Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.42)
# 887
Out of 4,667 analysts
52
Total ratings
51.35%
Success rate
4.33%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Maintains: Neutral | $340 → $380 | $357.77 | +6.21% | 3 | Nov 4, 2024 | |
| TXG 10x Genomics | Maintains: Neutral | $20 → $14 | $13.32 | +5.11% | 2 | Oct 30, 2024 | |
| TMO Thermo Fisher | Maintains: Overweight | $650 → $670 | $512.84 | +30.65% | 8 | Sep 20, 2024 | |
| HSIC Henry Schein | Maintains: Overweight | $88 → $80 | $73.73 | +8.50% | 3 | Aug 12, 2024 | |
| NVST Envista Holdings | Downgrades: Neutral | $23 → $16 | $20.37 | -21.45% | 3 | Aug 8, 2024 | |
| TEM Tempus AI | Maintains: Overweight | $42 → $47 | $58.15 | -19.17% | 2 | Aug 7, 2024 | |
| MYGN Myriad Genetics | Maintains: Underweight | $17 → $20 | $15.30 | +30.72% | 3 | Aug 7, 2024 | |
| AKYA Akoya Biosciences | Downgrades: Neutral | n/a | $2.16 | - | 2 | Aug 6, 2024 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,300 → $1,400 | $1,166.90 | +19.98% | 2 | Aug 5, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $5 → $6 | $4.42 | +35.75% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $200 | $138.90 | +43.99% | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $111.34 | +7.78% | 3 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $155 | $128.57 | +20.56% | 5 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.72 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $53.37 | +68.63% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $233.10 | +15.83% | 4 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $45 | $59.00 | -23.73% | 1 | May 22, 2023 |
Waters
Nov 4, 2024
Maintains: Neutral
Price Target: $340 → $380
Current: $357.77
Upside: +6.21%
10x Genomics
Oct 30, 2024
Maintains: Neutral
Price Target: $20 → $14
Current: $13.32
Upside: +5.11%
Thermo Fisher
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $512.84
Upside: +30.65%
Henry Schein
Aug 12, 2024
Maintains: Overweight
Price Target: $88 → $80
Current: $73.73
Upside: +8.50%
Envista Holdings
Aug 8, 2024
Downgrades: Neutral
Price Target: $23 → $16
Current: $20.37
Upside: -21.45%
Tempus AI
Aug 7, 2024
Maintains: Overweight
Price Target: $42 → $47
Current: $58.15
Upside: -19.17%
Myriad Genetics
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $15.30
Upside: +30.72%
Akoya Biosciences
Aug 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.16
Upside: -
Mettler-Toledo International
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,166.90
Upside: +19.98%
Adaptive Biotechnologies
Aug 2, 2024
Maintains: Overweight
Price Target: $5 → $6
Current: $4.42
Upside: +35.75%
Jul 31, 2024
Maintains: Overweight
Price Target: $190 → $200
Current: $138.90
Upside: +43.99%
Jul 30, 2024
Maintains: Neutral
Price Target: $105 → $120
Current: $111.34
Upside: +7.78%
May 30, 2024
Maintains: Overweight
Price Target: $165 → $155
Current: $128.57
Upside: +20.56%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.72
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $53.37
Upside: +68.63%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $233.10
Upside: +15.83%
May 22, 2023
Downgrades: Neutral
Price Target: $90 → $45
Current: $59.00
Upside: -23.73%